Vitamin B12 Explained: Understanding Your Vitamin B12 Blood Test Results

This guide is for general health education only. It does not diagnose vitamin B12 deficiency, explain the cause of an individual's abnormal result, or recommend personalised treatment or supplementation.

Blood-test results should be interpreted using the reference range supplied by the laboratory and in the context of symptoms, medical history, medications, diet and other investigations.

If you have neurological symptoms such as new weakness, difficulty walking, significant balance problems, worsening numbness, visual disturbance or rapidly progressing symptoms, seek medical assessment rather than relying on an online interpretation.

Vitamin B12 is the collective name for a family of cobalt-containing compounds called cobalamins. Biologically active forms include methylcobalamin and adenosylcobalamin, while cyanocobalamin and hydroxocobalamin can be converted into active forms in the body.

Vitamin B12 participates in several fundamental biological processes. It is required for normal DNA synthesis, healthy formation of red blood cells and development, myelination and function of the central nervous system. It also acts as a cofactor in reactions involving methionine and methylmalonyl-CoA metabolism.

This helps explain why deficiency can produce apparently unrelated symptoms.

Someone with B12 deficiency might develop fatigue because blood-cell production is impaired. Another person might experience pins and needles because neurological function is affected. Someone else may experience cognitive difficulties. And some people have no obvious symptoms when a low level is first discovered.

One of the most important changes in modern understanding of B12 deficiency is recognition that neurological deficiency can exist without the classic blood-count abnormalities traditionally associated with it. NICE explicitly advises clinicians not to rule out deficiency solely because anaemia or macrocytosis is absent.

B12 absorption is considerably more complicated than simply eating a food containing the vitamin.

Vitamin B12 from food must first be released from food proteins during digestion. It eventually binds to intrinsic factor, a protein produced by specialised cells in the stomach. The B12–intrinsic-factor complex then travels through the digestive tract and is absorbed primarily in the terminal portion of the small intestine, the ileum.

This pathway explains why a person can consume enough vitamin B12 yet still become deficient.

Problems can occur at several points:

The stomach: autoimmune gastritis can damage the cells involved in acid and intrinsic-factor production.

After stomach surgery: removing part or all of the stomach can interfere with the normal absorption pathway.

The intestine: conditions affecting the ileum or other gastrointestinal disease can impair absorption.

Medications: some medicines can interfere with B12 availability or absorption.

Functional inactivation: nitrous oxide can interfere with B12 function even when the conventional blood concentration does not tell the whole story.

The body can also store substantial quantities of B12. NHS guidance notes that stores may last approximately 2–5 years, which helps explain why dietary deficiency may emerge slowly rather than within weeks of changing diet.

The standard test generally measures the concentration of total vitamin B12 in serum or plasma.

But there is an important limitation:

A blood concentration does not perfectly measure how much biologically usable B12 is reaching every cell.

This is why interpreting B12 can sometimes require additional information. NICE recognises both total B12 and active B12 as initial diagnostic tests, with active B12 preferred as the initial test during pregnancy.

Active B12—also called holotranscobalamin—measures the fraction of circulating B12 bound to transcobalamin that is available for cellular uptake.

When an initial B12 result is uncertain, metabolic markers can provide another layer of information.

Two commonly discussed markers are:

NIH identifies MMA as a particularly sensitive marker of B12 status, while NICE recommends considering serum MMA when symptoms or signs are present alongside an indeterminate initial B12 result.

This is where interpretation becomes particularly important.

There is no single universal B12 reference range applicable to every laboratory, assay and patient.

Always look at the range printed alongside your own result.

However, NICE provides useful thresholds for interpreting initial tests in adults.

NICE thresholds for total vitamin B12

NICE emphasises that these thresholds should be used alongside clinical assessment and laboratory guidance.

NIH similarly notes that cut-offs vary by assay and laboratory. Many laboratories consider concentrations below approximately 200–250 pg/mL (148–185 pmol/L) subnormal, demonstrating why a number cannot be interpreted without knowing the method and reference interval.

Important unit note

For vitamin B12:

1 pg/mL = 1 ng/L.

So a result reported as 250 pg/mL is numerically the same as 250 ng/L.

Results expressed in pmol/L, however, use a different numerical scale.

Borderline B12 results are one of the most confusing areas of blood-test interpretation.

Imagine a result of:

Vitamin B12: 240 ng/L

It may fall within a laboratory's reference interval, yet under NICE's diagnostic framework it lies in the indeterminate range.

That does not mean the person definitely has deficiency.

It means the result alone may not provide a sufficiently confident answer.

Clinical interpretation might therefore consider:

symptoms, diet, medications, gastrointestinal disease, previous gastrointestinal surgery, pregnancy or breastfeeding, neurological findings, full blood count, folate, and potentially MMA testing.

NICE recommends considering serum MMA when someone has symptoms or signs compatible with deficiency and an indeterminate total or active B12 result.

Reference intervals are valuable tools, but B12 illustrates why laboratory medicine cannot always be reduced to green and red numbers.

Methylmalonic acid is a metabolic compound whose concentration tends to increase when vitamin B12-dependent metabolism is impaired.

NIH describes serum MMA as the most sensitive commonly used marker of B12 status and notes that it can help confirm deficiency when conventional B12 results are borderline.

But MMA is not perfect.

Kidney impairment can increase MMA independently of B12 deficiency, and concentrations tend to rise with age. This means an elevated MMA also needs clinical interpretation.

Homocysteine is another potential marker. It can rise when B12 status declines, but it is less specific because folate status, kidney function and other factors can affect it.

Vitamin B12 deficiency can present in many different ways, and NICE stresses that its symptoms are not specific to B12 deficiency.

Possible manifestations include:

Blood-related symptoms

Deficiency can interfere with normal red blood cell production and cause megaloblastic anaemia.

Possible symptoms associated with anaemia include:

fatigue, reduced energy, weakness, breathlessness, paleness, and sometimes palpitations.

NHS guidance explains that B12 deficiency can cause abnormally large red cells that do not function normally.

Neurological symptoms

B12 is important for nervous-system function. Deficiency can be associated with:

pins and needles, numbness, impaired sensation, balance difficulties, unsteady gait, coordination problems, visual disturbance, and, in severe cases, spinal-cord involvement.

NICE specifically identifies paraesthesia, impaired gait, balance problems, falls and sensory ataxia among recognised neurological presentations.

Cognitive and psychological symptoms

Possible manifestations include:

difficulty concentrating, short-term memory problems, "brain fog", depression, anxiety, confusion, and, less commonly, more severe neuropsychiatric disturbance.

These symptoms have many possible causes and are not evidence of B12 deficiency by themselves.

Mouth and tongue changes

A sore, smooth or red tongue—glossitis—and mouth ulcers can occur.

Yes.

This is one of the most clinically important points in this entire guide.

Historically, B12 deficiency was strongly associated with macrocytic or megaloblastic anaemia. That association is real, but it is incomplete.

NICE explicitly states:

Do not rule out vitamin B12 deficiency based solely on the absence of anaemia or macrocytosis.

Neurological abnormalities may therefore be clinically important even when haemoglobin and mean corpuscular volume (MCV) are normal.

This is also why taking folic acid without recognising an underlying B12 deficiency can be problematic: folate may improve the haematological picture while neurological B12 deficiency remains untreated. NHS guidance therefore advises checking B12 status when appropriate before treating folate deficiency.

Low B12 is not a diagnosis by itself. Identifying why it is low can be just as important as confirming deficiency.

1. Low dietary intake

Natural B12 sources are predominantly animal-derived foods.

NHS sources include:

meat, fish, milk, cheese, eggs, and fortified breakfast cereals.

People following a vegan diet can obtain B12 through appropriately fortified foods or supplementation, but an unfortified vegan diet contains very little reliable B12. NICE therefore includes diets excluding or low in animal-source foods among recognised risk factors.

For UK adults aged 19–64, NHS guidance states that approximately 1.5 micrograms per day is required.

2. Autoimmune Gastritis

Autoimmune gastritis is an important cause of B12 malabsorption.

The immune system targets components of the stomach, including parietal cells and/or intrinsic factor. Damage to these cells can reduce stomach acid and intrinsic-factor production, interfering with B12 absorption.

Historically, the term pernicious anaemia has often been used in this context.

However, NICE's 2024 guideline deliberately prefers autoimmune gastritis, noting that pernicious anaemia is technically a possible consequence of severe chronic deficiency rather than a precise synonym for the underlying gastric autoimmune disease.

Anti-intrinsic-factor antibody testing may help investigate suspected autoimmune gastritis, although NICE cautions that a negative test does not completely exclude it.

3. Gastrointestinal Surgery

Operations affecting the stomach or terminal ileum can substantially alter B12 absorption.

Examples include:

total gastrectomy, partial gastrectomy, terminal ileal resection, and some bariatric operations.

NICE considers deficiency highly likely following total gastrectomy or complete terminal ileal resection when B12 replacement is not being provided.

4. Gastrointestinal Conditions

Conditions associated with impaired absorption can increase the risk of deficiency.

NICE identifies coeliac disease and atrophic gastritis among recognised risk factors, while NHS guidance also notes that Crohn's disease can impair B12 absorption.

5. Metformin

Metformin deserves particular attention because it is so widely used.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) states that reduced B12 levels are now considered a common side effect of metformin, with risk increasing with higher doses, longer duration of therapy and additional B12 risk factors.

The MHRA advises testing B12 when deficiency is suspected—for example, in someone taking metformin who develops megaloblastic anaemia or new neuropathy—and considering periodic monitoring in people with risk factors.

This does not mean someone should stop metformin because their B12 is low. The MHRA specifically advises patients not to stop prescribed metformin without discussing it with their clinician.

6. Acid-Suppressing Medication

Proton-pump inhibitors and other gastric acid-suppressing medicines can interfere with the release and absorption of food-bound B12.

NHS and NIH both recognise prolonged acid suppression as a potential contributor to B12 deficiency.

Again, this is not a reason to stop prescribed medication independently. It is a factor clinicians can incorporate into the interpretation of an abnormal B12 result.

7. Nitrous Oxide

Recreational nitrous oxide use is an unusual but increasingly recognised cause of functional vitamin B12 deficiency.

Nitrous oxide can inactivate B12 within the body. NICE therefore recommends a different diagnostic approach when nitrous oxide is suspected: plasma homocysteine or serum MMA may be used as the initial test rather than relying solely on conventional serum B12.

This distinction matters because a conventional B12 concentration may not accurately reflect whether the vitamin is functioning normally.

Risk increases in several circumstances:

NICE estimates B12 deficiency affects approximately 5% of people aged 65–74 and more than 10% of those aged 75 or older, although prevalence estimates vary according to the population and diagnostic definition used.

Pregnancy changes the interpretation and importance of many nutritional biomarkers.

NICE recommends active B12 as the initial diagnostic test when B12 deficiency is suspected during pregnancy. It also advises clinicians to consider replacement while further testing is underway in pregnant or breastfeeding people with indeterminate results when appropriate.

NIH notes that adequate B12 status is important for maternal and fetal health, although evidence regarding supplementation and many clinical pregnancy outcomes remains limited.

Pregnancy is therefore a setting in which individual laboratory interpretation and professional assessment are particularly important.

People understandably focus on low B12, but blood tests occasionally show unexpectedly high concentrations.

The first question is simple:

Are you taking B12?

Tablets, multivitamins, fortified products and particularly injections can substantially increase circulating B12.

A high serum concentration after supplementation is therefore not equivalent to "B12 toxicity."

NIH notes that vitamin B12 has not been assigned a tolerable upper intake level because of its generally low toxicity potential. NHS guidance similarly states that evidence of harm from high supplemental doses is limited and considers supplements containing 2 mg/day or less unlikely to cause harm.

However, an unexplained persistent high B12 concentration in someone not supplementing should not automatically be interpreted as excellent B12 status. Serum B12 can be influenced by circulating binding proteins and underlying medical conditions. The appropriate response is clinical interpretation rather than attempts to lower the number independently.

Importantly, observational associations between elevated B12 concentrations and disease do not prove that B12 itself caused the disease. NIH describes evidence linking high circulating B12 with cancer as mixed and inconsistent.

These conditions overlap but are not interchangeable.

NHS notes that neurological complications from prolonged B12 deficiency can sometimes become irreversible, which is one reason prompt recognition matters.

B12 deficiency can affect a full blood count.

Possible findings include:

reduced haemoglobin, macrocytosis, elevated mean corpuscular volume (MCV), and megaloblastic changes.

But none is mandatory.

A normal MCV does not exclude deficiency.

This becomes especially important when another condition changes red-cell size in the opposite direction. For example, simultaneous iron deficiency may complicate the classic macrocytic pattern.

The safest principle is therefore:

Interpret the entire blood-test pattern rather than one marker.

A simplified diagnostic pathway may look like this:

Symptoms or risk factors

↓

Total B12 or active B12

↓

Clearly low result → investigate likely cause

Borderline/indeterminate result → consider MMA and clinical context

Result suggesting deficiency unlikely → investigate other explanations if symptoms persist

↓

Determine cause

dietary? autoimmune gastritis? gastrointestinal disease? surgery? medication? nitrous oxide? another explanation?

NICE recommends obtaining diagnostic blood samples before starting replacement whenever possible, because supplements can raise circulating B12 and complicate interpretation. However, treatment should not be delayed when suspected megaloblastic anaemia is accompanied by significant neurological symptoms, particularly when spinal-cord involvement is suspected.

Treatment depends heavily on why deficiency developed.

Options can include oral B12 replacement or intramuscular injections.

NICE recommends lifelong intramuscular B12 replacement when deficiency results from autoimmune gastritis, total gastrectomy or complete terminal ileal resection. Other forms of malabsorption may be managed with replacement chosen according to the individual circumstances.

Diet-related deficiency may be managed differently from irreversible malabsorption.

This distinction explains why copying another person's supplement dose—or treating a laboratory number without investigating its cause—is poor practice.

"How much B12 should I take?"

It is:

"Why is my B12 low?"

A dietary deficiency and an irreversible absorption disorder can produce the same laboratory result but require very different long-term strategies.

Response varies.

Blood abnormalities may improve before neurological symptoms. Some symptoms can take considerably longer to recover, and neurological injury from prolonged severe deficiency may sometimes be irreversible.

NICE advises people starting replacement that symptoms may begin improving within approximately 2 weeks but can take up to 3 months to improve, and that complete resolution can take longer depending on the underlying problem and severity.

Persistent, worsening or new symptoms warrant reassessment rather than simply assuming more B12 is required.

A laboratory number should never be assessed in isolation, but particular attention is warranted when possible B12 deficiency occurs alongside:

new or progressive numbness, pins and needles, weakness, difficulty walking, balance deterioration or falls, visual disturbance, substantial cognitive changes, significant anaemia, or rapidly worsening neurological symptoms.

NICE specifically advises not delaying B12 replacement while waiting for results when megaloblastic anaemia and neurological symptoms suggest serious B12 deficiency, particularly possible subacute combined degeneration of the spinal cord.

This does not mean every episode of tingling is an emergency. It means neurological symptoms should not be dismissed solely because a B12 number looks borderline or because anaemia is absent.

Continue building the picture with related Healio360 guides:

Blood Tests & Biomarkers

HbA1c Explained: Understanding Your Blood Sugar Over Time Ferritin Explained: Understanding Your Iron Stores High Creatinine: What an Elevated Creatinine Blood Test Means Liver Enzymes Explained Vitamin D Explained Folate Blood Test Explained Complete Blood Count Explained MCV Explained: What High and Low MCV Can Mean Iron, Ferritin, Transferrin and TIBC Explained Thyroid Function Tests Explained

Understanding Medical Reports

What Does "Unremarkable" Mean on a Scan? What Does "Mild Degenerative Changes" Mean? What Does "Clinical Correlation Recommended" Mean?

One blood test is a snapshot. Your health is a timeline.

A vitamin B12 result becomes more meaningful when you can see it alongside your previous results, full blood count, folate, ferritin, symptoms, medications and other health information.

Healio360 helps bring those pieces together.

Upload and organise medical reports, understand complex terminology in plain language, follow biomarkers over time and build a longitudinal picture of your health information.

Instead of asking only:

"Is my B12 normal?"

you can begin asking:

"How has it changed?"

"What other results changed with it?"

"Is this an isolated result or part of a pattern?"

"What should I discuss with my healthcare professional?"

Turn fragmented health information into a clearer, connected health story.

Healio360 provides educational health information and organisational tools. It does not diagnose medical conditions, replace a healthcare professional or provide personalised treatment recommendations.